gms | German Medical Science

65th Annual Meeting of the German Association for Medical Informatics, Biometry and Epidemiology (GMDS), Meeting of the Central European Network (CEN: German Region, Austro-Swiss Region and Polish Region) of the International Biometric Society (IBS)

06.09. - 09.09.2020, Berlin (online conference)

Effectiveness of care in oncological centres – first results from the WiZen study

Meeting Abstract

  • Veronika Bierbaum - Zentrum für Evidenzbasierte Gesundheitsversorgung (ZEGV), Universitätsklinikum und Medizinische Fakultät Carl Gustav Carus an der TU Dresden, Dresden, Germany
  • Olaf Schoffer - Zentrum für Evidenzbasierte Gesundheitsversorgung (ZEGV), Universitätsklinikum und Medizinische Fakultät Carl Gustav Carus an der TU Dresden, Dresden, Germany
  • Christoph Forkert - Zentrum für Evidenzbasierte Gesundheitsversorgung (ZEGV), Universitätsklinikum und Medizinische Fakultät Carl Gustav Carus an der TU Dresden, Dresden, Germany
  • Michael Gerken - Tumorzentrum Regensburg – Institut für Qualitätssicherung und Versorgungsforschung der Universität Regensburg, Regensburg, Germany
  • Kees Kleihues van Tol - Arbeitsgemeinschaft Deutscher Tumorzentren e.V., Berlin, Germany
  • Patrik Dröge - Wissenschaftliches Institut der AOK, Berlin, Germany
  • Thomas Ruhnke - Wissenschaftliches Institut der AOK, Berlin, Germany
  • Andreas Klöss - Wissenschaftliches Institut der AOK, Berlin, Germany
  • Christian Günster - Wissenschaftliches Institut der AOK (WIdO), Berlin, Germany
  • Monika Klinkhammer-Schalke - Tumorzentrum Regensburg – Institut für Qualitätssicherung und Versorgungsforschung der Universität Regensburg, Regensburg, GermanyArbeitsgemeinschaft Deutscher Tumorzentren e.V., Berlin, Germany
  • Jochen Schmitt - Zentrum für Evidenzbasierte Gesundheitsversorgung (ZEGV), Universitätsklinikum und Medizinische Fakultät Carl Gustav Carus an der TU Dresden, Dresden, Germany

Deutsche Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie. 65th Annual Meeting of the German Association for Medical Informatics, Biometry and Epidemiology (GMDS), Meeting of the Central European Network (CEN: German Region, Austro-Swiss Region and Polish Region) of the International Biometric Society (IBS). Berlin, 06.-09.09.2020. Düsseldorf: German Medical Science GMS Publishing House; 2021. DocAbstr. 441

doi: 10.3205/20gmds238, urn:nbn:de:0183-20gmds2387

Veröffentlicht: 26. Februar 2021

© 2021 Bierbaum et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Background: Cancer constitutes the second most frequent cause of death in Germany. Healthcare nowadays is facing the challenge of an increasing number of cancer patients, but also the implementation of quickly emerging innovative therapies. To maintain a high quality of treatment, the national cancer plan aims at a unified certification of cancer centres. The effects of treatments in certified centres have not yet been investigated across large populations and different cancer entities. So far, studies on breast and colon cancer have shown associations with improved survival rates of patients treated in certified centers. The project “Wirksamkeit der Versorgung in onkologischen Zentren” (WiZen, “Effectiveness of care in oncological centres”) aims to close this gap.

Methods: In a retrospective comparative cohort study, incident cases of eight types of cancer diagnosed within 2008-2017 are analyzed based on nationwide health insurance data provided by WIdO (the AOK research institute) and data from regional clinical cancer registries. We present analyses based on secondary data from the statutory health insurance fund for colon, rectal and pancreatic cancer with 150 000 continuously insured patients for colon and rectal cancer (ICD-10: C18-C20) and 50,000 patients for pancreatic cancer (ICD-10: C25). We discuss methods to identify incident cases in datasets with restricted observation period.

Results: Differences between the survival distribution, 1 and 5 year survival rates and 30-day mortality from initial treatment are computed for certified centers compared to non-certified clinics. It is outlined to what extent the severity of the disease, which is not explicitly recorded in the health insurance data, can be captured.

Conclusion: The breadth of the database and complexity of analyses give reason to expect reliable new evidence for cancer care. First unadjusted results show differences with respect to the treatment in (non-)certified clinics. A verification based on adjusted models is in progress.

The authors declare that a positive ethics committee vote has been obtained.